EAM
MLYS icon

Erste Asset Management’s Mineralys Therapeutics MLYS Stock Holding History

Erste Asset Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.21M Hold
45,000
– – 0.01% 438
2026
Q1 		$1.06M Hold
45,000
– – 0.01% 438
2025
Q4 		$1.66M Hold
45,000
– – 0.01% 377
2025
Q3 		$1.77M Hold
45,000
– – 0.02% 355
2025
Q2 		$617K Hold
45,000
– – 0.01% 593
2025
Q1 		$660K Buy
+45,000
New +$518K 0.01% 412

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Erste Asset Management's MLYS Position: Q2 2026 in Review

Erste Asset Management held its Mineralys Therapeutics (MLYS) position steady in Q2 2026 at 45,000 shares worth $1.21M. The position accounts for 0.01% of the portfolio, ranked #438.

Erste Asset Management first reported a position in MLYS in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.77M in Q3 2025. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Erste Asset Management held 45,000 shares of Mineralys Therapeutics worth $1.21M as of Q2 2026.
  • Erste Asset Management left its Mineralys Therapeutics share count unchanged in Q2 2026.
  • Mineralys Therapeutics made up 0.01% of Erste Asset Management's portfolio in Q2 2026, its #438 holding.
  • Erste Asset Management first reported a position in Mineralys Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Erste Asset Management's Mineralys Therapeutics position peaked at $1.77M in Q3 2025.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Erste Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.